

INVESTOR RELATIONS

MetrioPharm Investor Relations News QIV 2020

Greetings by CEO Dr. Wolfgang Brysch

Dear Shareholders,

Shortly after the Corona pandemic hit Europe this spring, two things became clear for us: first, that new medical approaches would be needed to address this crisis in the long term.

Second, some early research suggested that there might be a link between severe disease progression and oxidative stress. This meant that our lead compound was potentially suitable for treating Covid-19 patients. MetrioPharm was faced with the question: is MP1032 a viable candidate for clinical development in Covid-19?

Our team has worked diligently over the past several months to provide an informed answer. We have evaluated clinical data, conducted new preclinical research, published results and evaluated potential study designs.

By year-end, we have certainty: our lead compound MP1032 is a highly promising candidate for the treatment of Covid-19.

In December, the company was able to announce the plans for a Phase II clinical trial. A financing round to conduct this trial has been initiated and is currently ongoing.

Experts agree that demand for therapeutics for treating Covid-19 will persist for many years to come. With focused and rapid development, MetrioPharm aims to help relieve the burden on healthcare systems worldwide and help patients. I am confident that we will soon be able to report interesting news on this project.

But for now, I wish you all good health through the coming weeks and into the new year!

Best regards

Dr. Wolfgang Brysch

CEO

MetrioPharm in the Media

The publication of our preclinical data of MP1032 in Covid-19 resulted in some media placements. Please read the article in the Swiss publication Finanz und Wirtschaft [here](#), as well as a publication in the German Frankfurter Rundschau [here](#).

MetrioPharm Blog

An important part of MetrioPharm's public relations is its [blog](#). Here, important topics concerning the development of MP1032 as well as the structural development of MetrioPharm are addressed. Our ["Six questions and answers from MetrioPharm CEO Dr. Wolfgang Brysch on the active ingredient MP1032 at Covid-19"](#) in November of this year generated a particularly great interest.

MetrioPharm on LinkedIn

A promising addition as part of our public relations efforts is LinkedIn, a digital network for professional contacts and publications. MetrioPharm has also been able to publish some highly frequented posts on this platform in recent months. Please follow us [here](#) on LinkedIn.

Your contact:



Eva Brysch
Head of Investor Relations & Corporate Communications
Tel.: +49-(0)30-3384-395-40
E-Mail: invest@metriopharm.com